Synlogic stock.

SYBX Stock 12 Months Forecast. $21.67. (983.50% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Synlogic in the last 3 months. The average price target is $21.67 with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 983.50% change from the last price of $2.00.Chardan Raises Price Target on Synlogic to $6 From $5.50 Reflecting Lower Cash Burns Due to Recent Downsizing, Keeps Buy Rating. Jun. 06. MT. SVB Securities Cuts Synlogic's Price Target to $4 From $8, Maintains Outperform Rating. May. 12. MT. HC Wainwright Lowers Synlogic's Price Target to $5 From $7, Buy Rating Kept.- Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, …Website. n/a. 72. Aoife Brennan. https://www.synlogictx.com. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate ...

The Investor Relations website contains information about Synlogic's business for stockholders, potential investors, and financial analysts.2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Oct 20, 2022 · Synlogic was spun out of MIT and uses technology developed by Drs. Tim Lu and Jim Collins. Synlogic was founded in 2014 and became a public company via a reverse merger in 2017. The first ... In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Synlogic (SYBX – Research Report), with a price target of $24.00. Ed Arce has given his Buy rating due to a ...

Synlogic, Inc. (SYBX) is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases. The stock price, news, quote and history of SYBX are available on Yahoo Finance. See the latest performance outlook, earnings date, dividend yield and more. Find the latest Synlogic, Inc. (SYBX) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest Synlogic Inc (MINA.BE) stock quote, history, news and other vital information to help you with your stock trading and investing.May 11, 2023 · CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today reported financial results for the ... The company earned $0.39 million during the quarter, compared to analysts' expectations of $0.04 million. Synlogic has generated ($12.76) earnings per share over the last year (($12.76) diluted earnings per share). Earnings for Synlogic are expected to grow in the coming year, from ($6.25) to ($5.32) per share.

Mar 29, 2023 · Fourth Quarter 2022 Financial Results. As of December 31, 2022, Synlogic had cash, cash equivalents, and short-term marketable securities of $77.6 million. Revenue was $0.1 million for the three ...

Kelly’s belief in synthetic biology is unflagging, and his support has continued even as Synlogic’s stock price has slumped, erasing about three quarters of Ginkgo’s investment on paper.

Nov 9, 2023 · Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November. Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug ...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.A rating of 71 puts Synlogic Inc near the top of the Biotechnology industry according to InvestorsObserver. Synlogic Inc's score of 71 means it scores higher than 71% of stocks in the industry. Synlogic Inc also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 17 out of the 148 industries.DJ. Earnings Flash (SYBX) SYNLOGIC Posts Q3 Revenue $393,000. Nov. 09. MT. Synlogic, Inc. Reports Earnings Results for the Third Quarter and Nine Months …

2.46. +0.16. +6.96%. Get Synlogic Inc (SYBX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.When it comes to purchasing a new vehicle, finding the perfect car that meets all your requirements can be a daunting task. If you have your heart set on a Genesis GV70, you’ll want to ensure that you find the best one available in stock.On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the “Reverse Stock Split”), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).Stock Quote & Chart Analyst Coverage. Corporate Governance. Governance Highlights Leadership Board of Directors Committee Composition Board Diversity Matrix. ... Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update. November 30, 2022.Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.

Apr 25, 2023 · In discussing Synlogic (NASDAQ: SYBX) stock, let’s begin with the upside because it’s substantial. SYBX shares carry an average target price of $7.17 yet trade for $0.65. They are therefore a ...

We don’t just envision the possibilities, we create them. Founded in 2014 by two of the world’s foremost experts in synthetic biology, James Collins, PhD, and Tim Lu, MD, PhD, of the Massachusetts Institute of Technology, Synlogic is comprised of visionary scientists – pioneering biologists and genetic engineers working to transform drug ...Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 7.69% and 73.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?Synlogic Announces Reverse Stock Split. CAMBRIDGE, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non ...Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis.Synlogic trades on the NASDAQ stock market under the symbol SYBX. What is Synlogic stock price doing today? As of November 24, 2023, SYBX stock price declined to $2.00 with 12,590 million shares trading.

Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 10, 2022 . Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Website. n/a. 72. Aoife Brennan. https://www.synlogictx.com. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate ...

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines that are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug ...View the latest Synlogic Inc. (SYBX) stock price, news, historical charts, analyst ratings and financial information from WSJ.TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comSYBX | Overview of Synlogic Inc stock by Investoreight. View stock price, financials, news, earnings, and performance of Synlogic Inc - Investoreight.Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration. CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a ...Find the latest Synlogic, Inc. (SYBX) stock quote, history, news and other vital information to help you with your stock trading and investing.2 equities research analysts have issued twelve-month price targets for Synlogic's shares. Their SYBX share price targets range from $75.00 to $90.00. On average, they anticipate the company's share price to reach $82.50 in the next year. This suggests a possible upside of 3,351.9% from the stock's current price.Synlogic, Inc. Common Stock (SYBX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Synlogic saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 90,800 shares, a decline of 41.7% from the previous total of 155,700 shares. Changes in short volume can be used to identify positive and negative investor sentiment.

Nov 30, 2023 · View Synlogic, Inc SYBX investment & stock information. Get the latest Synlogic, Inc SYBX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Synlogic Inc stock performance at a glance. Check Synlogic Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Instagram:https://instagram. asvixtflo etfforeign exchange trading tipsthree sixty solar stock Synlogic Stock Probability Of Bankruptcy ... Stocks USA . ... Synlogic Probability Of Bankruptcy is used to show its chance of financial distress over the next two ...Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen. aistockqsi stock forecast Nov 30, 2023 · Grading Synlogic Inc Stock. Before you choose to buy, sell or hold Synlogic Inc stock, you’ll want to analyze how it has been graded. Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, making sense of financial ratios, reading income statements and analyzing recent stock movement. - Synlogic Commences Trading on NASDAQ Capital Market under Ticker Symbol “SYBX” - Combined Company has Approximately $100 Million in Cash and Cash Equivalents Following Transaction Close - Company Strengthens Board of Directors with addition of Michael Powell, Ph.D., and Richard Shea. CAMBRIDGE, Mass. & AUSTIN, … national fuel and gas CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to ...